A team of physicists at the Institut Lumière Matière (CNRS/Université Claude Bernard Lyon 1), in collaboration with the Cancer Research Center of Lyon (CNRS/INSERM/ Université Claude Bernard Lyon 1/Centre Léon Bérard/Hospices civils de Lyon), has demonstrated the potential, for oncology, of an imaging technique based only on the physical properties of tumors. It can differentiate populations of malignant cells and monitor how effective an anticancer treatment is. These results, published in Physical Review Letters on January 8, 2019, should help in the design of new therapeutic molecules and in the personalization of treatments.
Despite a good understanding of the biology of cancer, 90% of experimental drugs fail during clinical trials. It is also increasingly suspected that the mechanical properties of tumors influence disease progression, and treatment efficacy. Although we can evaluate tumor elasticity globally, it is more difficult to measure local rigidity deep down and to see whether the core of the tumor resists the penetration of therapeutic liquids. To probe these physical properties, the researchers have used a noncontact imaging technique that does not require the use of contrast agents – therefore that does not disturb tissue function – that exploits natural infinitesimal vibrations of matter.
To recapitulate the behavior of colorectal tumors in vitro, the researchers created organoids, spheres with diameter 0.3 mm formed by the aggregation of tumor cells. They focused a red laser beam onto these objects. The infinitesimal vibrations of the sample, generated by thermal agitation, modify very slightly the color of the light beam that exits the sample. By analyzing this light, a map of the mechanical properties of the model tumors is created: the more rigid the area scanned by the laser, the faster the vibrations and, in a manner comparable to the Doppler effect (the mechanism that makes a siren sound increasingly shrill as it gets closer), the greater the color change.
From organoids composed of two cell lines with different malignancies, the researchers have shown that they could distinguish the two cell types from their mechanical properties. Such information is crucial because it may allow diagnosis from biopsy analysis to be refined and offer better assessment of tumor grade. Local variations in mechanical properties after a drug treatment have also been monitored using this technique: the center of the tumor remains rigid longer than the edge, demonstrating the treatment’s efficacy gradient. So local measurement of mechanical properties could confirm the total destruction of the tumor and help in choosing as low a treatment dose and duration as possible.
This approach allows exploring the impact of mechanical properties on the therapeutic response. It should lead to more predictive in vitro tumor models for testing new therapeutic molecules and for combined therapies, which act for example on tissue rigidity to accelerate the penetration of active molecules in the center of the tumor. It could also provide new indicators to guide clinicians in personalization of therapies.
Learn more: Physics can show us the inside of tumors
The Latest on: Personalized cancer treatment
[google_news title=”” keyword=”personalized cancer treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized cancer treatment
- Final Trial Begins for World's First Skin Cancer Vaccine, Giving Hope to Those Affectedon April 26, 2024 at 7:59 pm
As this personalized mRNA vaccine enters its final trial phase, it brings promising prospects for individuals battling melanoma.
- UK Patients Testing World’s First Personalized mRNA Cancer Vaccine For Melanomaon April 26, 2024 at 1:26 pm
British patients are currently undergoing trials for a groundbreaking mRNA cancer vaccine tailored specifically for melanoma, with potential applications for lung, bladder, and kidney cancers as well.
- U.K. Tests World-First Personalized Skin Cancer Vaccineon April 26, 2024 at 9:08 am
Customized with genetic information from a patient’s own tumor, vaccines like this could one day be used against lung, kidney, bladder and colon cancer.
- World’s 1st skin cancer vaccine enters final trial, offers personalized cureon April 26, 2024 at 8:07 am
Scientists are testing the world's first skin cancer vaccine, which has entered global trial. They aim for personalized treatment.
- World-First mRNA Vaccine For Skin Cancer Commences Landmark Phase 3 Trialon April 26, 2024 at 7:02 am
A UK man has become one of the first to receive an experimental mRNA vaccine designed to prevent recurrence of melanoma skin cancer. Steve Young, a 52-year-old musician, had a stage II melanoma ...
- Ricoh and SimBioSys Partner on AI-Powered 3D Models for Personalized Breast Cancer Treatmenton April 26, 2024 at 6:59 am
By joining forces, these two companies are committed to pushing back the boundaries of medical innovation by combining SimBioSys’ cutting-edge artificial intelligence with Ricoh’s 3D printing know-how ...
- Revolutionary cancer cure? Personalized mRNA vaccine trials for melanoma underwayon April 26, 2024 at 6:07 am
Results from a phase 2 trial indicated a substantial decrease in the risk of melanoma recurrence for those who were vaccinated. A comprehensive phase 3 trial is now underway, conducted by the ...
- New Clinical Study Identifies Personalized Treatment Options for Metastatic Non-Small Cell Lung Cancer With Plasma Proteome Testingon April 25, 2024 at 7:40 am
Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist and hematologist Ernesto Bustinza-Linares, MD is co-author of a recent abstract published in the American Society of ...
- AI could predict whether cancer treatments will work, experts say: ‘Exciting time in medicine'on April 23, 2024 at 3:00 am
A chemotherapy alternative called immunotherapy is showing promise in treating cancer — and a new artificial intelligence tool could help ensure that patients have the best possible experience.
- How AI can help cancer patients receive personalized and precise treatment fasteron April 16, 2024 at 1:35 pm
Providence and Microsoft are developing research prototype AI tools to sort through growing mountains of patient data.
via Bing News